HomeNovelPictor Announces Seroprevalence Study Using New SARS-CoV-2 Antibody Test to Assess Antibody Levels in Kiwifruit
Pictor Announces Seroprevalence Study Using New SARS-CoV-2 Antibody Test to Assess Antibody Levels in Kiwifruit
December 22, 2022
Thursday 22 December 2022, 18:27 Press release: Pictor Limited
Pictor, a global leader in immunodiagnostics, today announced a major research project – the Pictor Antibody Clinical Trial (PACT-19) – which aims to gain important information and insights into the COVID-19 immune profile of New Zealanders.
“Serological testing measures antibody response in a person, and Pictor’s PACT-19 seroprevalence study will aid our understanding of the impact of vaccinations and infection on antibody levels in a New Zealand cohort,” said Howard Moore, CEO of Painter.
Additionally, as we learn more about COVID-19, seroprevalence studies may highlight the percentage of a population that could be protected from infection in the future, according to the World Health Organization (WHO).
The PACT-19 study is Pictor’s first national clinical study and uses the PictArray™ SARS-CoV-2 IgG antibody test, which was developed in-house and recently launched commercially in New Zealand. The test is the first of its kind as it enables personalized COVID-19 assessments by detecting whether a patient has antibodies from a previous SARS-CoV-2 infection (spike protein and nucleocapsid protein antibodies) or from vaccination alone (nucleocapsid protein antibodies only). peak). It also indicates whether at-risk patients have failed to mount a detectable antibody response despite vaccination or infection.
This study aims to monitor the change in participants’ antibody levels following vaccination alone or vaccination and infection with the COVID-19 virus. A total of 296 participants have been involved in the PACT-19 study to date. Of this group, 231 participants, who have been vaccinated but not infected, will be followed up for six months. The remaining 65, who were vaccinated and infected, were tested only once. Pictor was able to identify participants who had asymptomatic infections as well as participants who had symptoms but never tested positive on a PCR or rapid antigen test.
This study will conclude in mid-2023. “This study is especially important because it will add to our understanding of the significance and relevance of Spike protein and nucleocapsid protein antibodies, particularly with regards to viral protection and implications for conditions such as Long -COVID,” said PACT-19 Project Leader Helen Teale.